Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical advances in hematology & oncology : H&O

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 18185489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma

  2009cited by this paper
• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

  2006cited by this paper
• A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM).

  2006cited by this paper
• Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

  2006cited by this paper
• Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.

  2006cited by this paper
• An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.

  2006cited by this paper
• A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma.

  2006cited by this paper
• Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.

  2006cited by this paper
• Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.

  2006cited by this paper
• Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

  2006cited by this paper
• Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial.

  2006cited by this paper
• A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme.

  2006cited by this paper
• An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma.

  2006cited by this paper
• Imatinib plus hydroxyurea in pretreated non-progressive glioblastoma (GBM)-A single center phase II study.

  2006cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

  2005cited by this paper
• Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• The application of 5-bromodeoxyuridine in the management of CNS tumors

  2005cited by this paper
• A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.

  2004cited by this paper
• Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma

  2004cited by this paper
• Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: Report of the radiation therapy oncology group 98–03 protocol

  2004cited by this paper
• Current management of glioblastoma multiforme.

  2004cited by this paper
• Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme

  2004cited by this paper
• Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study.

  2004cited by this paper
• Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: Phase I/II-study.

  2004cited by this paper
• Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.

  2004cited by this paper
• Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

  2004cited by this paper
• Genetic and hypoxic regulation of angiogenesis in gliomas

  2004cited by this paper
• NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.

  2004cited by this paper
• Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery

  2003cited by this paper
• RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.

  2003cited by this paper
• Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.

  2003cited by this paper
• Motexafin gadolinium: a possible new radiosensitiser

  2003cited by this paper
• Blocked pathways: FTIs shut down oncogene signals.

  2003cited by this paper
• Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

  2003cited by this paper
• Novel chemotherapeutic agents for the treatment of glioblastoma multiforme

  2003cited by this paper
• Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

  2002cited by this paper
• Gamma Knife Stereotactic Radiosurgery for Patients with Glioblastoma Multiforme

  2002cited by this paper
• Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.

  2002cited by this paper
• Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

  2002cited by this paper
• Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

  2002cited by this paper
• The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine

  2002cited by this paper
• Phase II trial of motexafin gadolinium (MGd, xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM)

  2002cited by this paper
• The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

  2002cited by this paper
• A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.

  2002cited by this paper
• Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

  2002cited by this paper
• Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species.

  2001cited by this paper
• Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.

  2001cited by this paper
• Daily Low-dose Carboplatin as a Radiation Sensitizer for Newly Diagnosed Malignant Glioma

  2001cited by this paper
• Ras biochemistry and farnesyl transferase inhibitors: a literature survey

  2001cited by this paper
• Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

  2001cited by this paper
• Experimental validation of dose calculation algorithms for the GliaSite RTS, a novel 125I liquid-filled balloon brachytherapy applicator.

  2001cited by this paper
• Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.

  2001cited by this paper
• Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.

  2001cited by this paper
• Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

  2001cited by this paper
• Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme

  2001cited by this paper
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.

  2001cited by this paper
• MR-spectroscopy guided target delineation for high-grade gliomas.

  2001cited by this paper
• A Phase I dose escalation trial of motexafin gadolinium (gadolinium texaphyrin, xcytrinR)as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme

  2001cited by this paper
• Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

  2001cited by this paper
• Recent advances: Radiotherapy.

  2001cited by this paper
• The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

  2000cited by this paper
• High Dose Tamoxifen and Radiotherapy in Patients with Glioblastoma Multiforme: A Phase IB Study

  2000cited by this paper
• Survival of human glioma cells treated with various combination of temozolomide and X-rays.

  2000cited by this paper
• Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.

  2000cited by this paper
• Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

  2000cited by this paper
• Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies

  2000cited by this paper
• Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts

  2000cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas.

  2000cited by this paper
• A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas.

  2000cited by this paper
• Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.

  1999cited by this paper
• Extent of Resection as a Prognostic Variable in the Treatment of Gliomas

  1999cited by this paper
• Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases.

  1999cited by this paper
• A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.

  1999cited by this paper
• Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme.

  1999cited by this paper
• Topotecan for the Treatment of Recurrent or Progressive Central Nervous System Tumors – A Pediatric Oncology Group Phase II Study

  1999cited by this paper
• A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.

  1999cited by this paper
• Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.

  1999cited by this paper
• 2081 Pre-clinical evaluation of a novel device for delivering brachytherapy to resected brain tumor cavity margins

  1999cited by this paper
• Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins.

  1998cited by this paper
• Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line.

  1998cited by this paper
• DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

  1998cited by this paper
• Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

  1998cited by this paper
• Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.

  1998cited by this paper
• Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

  1998cited by this paper
• Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.

  1998cited by this paper
• Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma.

  1997cited by this paper
• Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol.

  1997cited by this paper
• The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma.

  1997cited by this paper
• Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation.

  1997cited by this paper
• In vitro evaluation of temozolomide combined with X-irradiation

  1997cited by this paper
• Somatic mutations of PTEN in glioblastoma multiforme.

  1997cited by this paper
• Protein prenylation: molecular mechanisms and functional consequences.

  1996cited by this paper
• Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02

  1996cited by this paper
• Phase II study of topotecan in patients with recurrent malignant glioma

  1996cited by this paper

• Advanced nanomicelles for targeted glioblastoma multiforme therapy.

  2025cites this paper
• Collagen-Based Drug Delivery Agents for Glioblastoma Multiforme Treatment

  2025cites this paper
• Impact of Hypertension on the Outcomes of Patients With High-Grade Gliomas: A Propensity-Matched Study From a Global Federated Health Research Network

  2025cites this paper
• Fibrin glue mediated direct delivery of radiation sensitizers results in enhanced efficacy of radiation treatment

  2024cites this paper
• Enhancing the Efficacy of Radiation Therapy by Photochemical Internalization of Fibrin-Hydrogel-Delivered Bleomycin

  2024influential citation
• Glioblastoma multiforme - a rare type of cancer: A narrative review

  2024cites this paper
• Interaction between FAK/αB-crystalline is important for viability of the glioblastoma cells

  2024cites this paper
• Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery

  2023cites this paper
• Therapeutic efficacy of 166Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model

  2022cites this paper
• The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma

  2021cites this paper
• Molecular biological investigation of temozolomide and kc7f2 combination in u87mg glioma cell line.

  2021cites this paper
• Development and Optimization of Irinotecan-Loaded PCL Nanoparticles and Their Cytotoxicity against Primary High-Grade Glioma Cells

  2021cites this paper
• Small Molecules of Marine Origin as Potential Anti-Glioma Agents

  2021cites this paper
• Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy

  2021cites this paper
• Radiosensitizing Effect of Bromelain Using Tumor Mice Model via Ki-67 and PARP-1 Inhibition

  2021cites this paper
• HOXA GENE EXPRESSION IMPLICATED IN TREATMENT RESISTANCE AND POOR PROGNOSIS IN GLIOBLASTOMA

  2020cites this paper
• Radioresistance in Glioblastoma and the Development of Radiosensitizers

  2020cites this paper
• Feasibility of intratumoral 165Holmium siloxane delivery to induced U87 glioblastoma in a large animal model, the Yucatan minipig

  2020cites this paper
• Evaluation of Brain Tumors by using Computed Tomography among Adult Saudi Patients

  2020cites this paper
• Polymeric Nanoparticles for the Treatment of Malignant Gliomas

  2020cites this paper
• INVESTIGATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY RELATED, EXOSOMAL MIRNAS IN NON-SMALL CELL LUNG CANCER (NSCLC) CASES

  2019cites this paper
• Glioblastoma diagnostics and prognostic biomarkers: Current status in medicine and exosome derivation

  2019cites this paper
• Characterization of an Orthotopic Rat Model of Glioblastoma Using Multiparametric Magnetic Resonance Imaging and Bioluminescence Imaging

  2018cites this paper
• Expression and tumor-promoting effects of caprin-1 in human glioma

  2018cites this paper
• Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications

  2018cites this paper
• Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment

  2017cites this paper
• Osteopontin Delocalization by Applied Low Intensity Static Magnetic Field in Cultured Human Glioblastoma Cells

  2017cites this paper
• In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme

  2017cites this paper
• Triple-negative breast cancer with brain metastasis in a pregnant woman

  2017cites this paper
• GBM radiosensitizers: dead in the water…or just the beginning?

  2017cites this paper
• Systemic Therapy after Radiotherapy Significantly Reduces the Risk of Mortality of Patients with 1–3 Brain Metastases: A Retrospective Study of 250 Patients

  2017influential citation
• Median survival after various methods of Table 1 : Neuroimaging and glioblastoma : Macdonald versus RANO criteria

  2016cites this paper
• Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells

  2016cites this paper
• Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.

  2016cites this paper
• Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM): Final Results of RTOG 0513

  2016cites this paper
• The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines

  2016cites this paper
• Radio-Resistance and Cancer Stem Cells: The Glioblastoma Model

  2016cites this paper
• Static magnetic field controls cell cycle in cultured human glioblastoma cells

  2016cites this paper
• Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

  2016cites this paper
• An alternative process of reduction of di-imines

  2015cites this paper
• Stereotactic Radiosurgery -A Review

  2015influential citation
• Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma

  2015cites this paper
• Radiosurgical Options in Neuro-oncology: A Review on Current Tenets and Future Opportunities. Part II: Adjuvant Radiobiological Tools

  2015cites this paper
• Biphasic effects of luteolin on interleukin-1β-induced cyclooxygenase-2 expression in glioblastoma cells.

  2015cites this paper
• Outcome of treatment with concurrent whole brain radiotherapy and Temozolomide in brain metastasis

  2015cites this paper
• Recurrent Glioblastoma: Where we stand

  2015cites this paper
• Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

  2015cites this paper
• Whole brain reirradiation and concurrent temozolomide in patients with brain metastases

  2014cites this paper
• Glioblastoma multiforme – an overview

  2014cites this paper
• Temozolomide for treatment of brain metastases: A review of 21 clinical trials.

  2014cites this paper
• Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas.

  2014cites this paper
• Increased survival using delayed gamma knife radiosurgery for recurrent high-grade glioma: a feasibility study.

  2014cites this paper
• Clinical Practice Of Chemotherapy With Temozolomide In China

  2014cites this paper
• New treatment modalities for brain tumors in dogs and cats.

  2014cites this paper
• Radiosensitising nanoparticles as novel cancer therapeutics--pipe dream or realistic prospect?

  2013cites this paper
• Glioblastoma multiforme in adults and the role of the advanced nurse practitioner

  2013cites this paper
• Novel Internalizing Human Antibodies Targeting Brain Tumor Sphere Cells

  2013cites this paper
• Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients.

  2013cites this paper
• Treatment Options in Newly Diagnosed Glioblastoma

  2013cites this paper
• Primary Brain Tumors

  2013cites this paper
• Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells.

  2013cites this paper
• Boron and Gadolinium Neutron Capture Therapy

  2013cites this paper
• Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.

  2013cites this paper
• Rapamycin inhibits the growth of glioblastoma.

  2013cites this paper
• Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control.

  2012cites this paper
• A combination of 2-deoxy-d-glucose and 6-aminonicotinamide induces cell cycle arrest and apoptosis selectively in irradiated human malignant cells

  2012cites this paper
• Behandlung von Hirntumorpatienten

  2012cites this paper
• Potential usefulness of radiosensitizers in glioblastoma.

  2012cites this paper
• The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma

  2012cites this paper
• Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASK1-JNK/p38MAPK signaling in head and neck cancer cells.

  2012cites this paper
• Glioblastoma multiforme: overview of current treatment and future perspectives.

  2012cites this paper
• Gold/ Copper Sulphide And Gold Nanoparticles For Application In Cancer Therapy

  2012cites this paper
• Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.

  2011cites this paper
• DNA Damage Response and Repair: Insights into Strategies for Radiation Sensitization

  2011cites this paper
• Glutamato induz radioresistência em glioblastomas humanos

  2011cites this paper
• DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.

  2011cites this paper
• Case of Advanced Recurrent Glioblastoma Successfully Treated with Monoterpene Perillyl Alcohol by Intranasal Administration

  2011cites this paper
• Motexafin gadolinium: a promising radiation sensitizer in brain metastasis

  2011cites this paper
• A miR-21 inhibitor enhances apoptosis and reduces G2-M accumulation induced by ionizing radiation in human glioblastoma U251 cells

  2011cites this paper
• Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

  2010cites this paper
• Stereotactic body radiation therapy: the report of AAPM Task Group 101.

  2010cites this paper
• Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report

  2010cites this paper
• Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells

  2010cites this paper
• Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

  2010cites this paper
• Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

  2009cites this paper
• Reoxygenation of Hypoxic Glioblastoma Multiforme Cells Potentiates the Killing Effect of an Interleukin-13-Based Cytotoxin

  2009cites this paper
• Ardipusilloside I induces apoptosis in human glioblastoma cells through a caspase-8-independent FasL/Fas-signaling pathway.

  2009cites this paper
• Treatment of High-Grade Gliomas in Adults

  2009cites this paper
• Radiosensitizers in Neurooncology

  2009cites this paper
• CURRENTCONCEPTS INSTEREOTACTICRADIOSURGERY- ANEUROSURGICAL ANDRADIOONCOLOGICALPOINT OFVIEW

  2009cites this paper
• 64 Radiosensitizers Neurooncology

  2009cites this paper
• Therapeutic advances in malignant glioma: current status and future prospects.

  2009cites this paper
• Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

  2009cites this paper
• Targeted therapy for neuro-oncology: reviewing the menu.

  2009cites this paper
• Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma

  2009cites this paper
• Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme.

  2009cites this paper
• Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view

  2009cites this paper
• Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility- weighted Contrast-enhanced

  2009cites this paper
• Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study

  2009cites this paper
• Adenoviral virotherapy for malignant brain tumors

  2009cites this paper